Crizotinib has been approved for marketing in China and is mainly used for the treatment of ALK positive non-small cell lung cancer. Patients need to purchase it through formal channels and strictly follow medical advice.

1. Listing status

(1) Approval time: crizotinib was approved in China in 2013 and is the first ALK inhibitor to be marketed domestically.

(2) Indications: Currently approved for first-line treatment of ALK positive advanced non-small cell lung cancer.

2. Medication Standards

(1) Prescription requirement: A prescription must be issued by a specialist oncologist and purchased from a qualified medical institution.

(2) Dosage standard: The recommended dosage is 250mg orally twice a day, and it should be swallowed whole.

3 purchasing channels

(1) Regular channels: can be purchased through the oncology department of a tertiary hospital or large chain pharmacies.

(2) Anti counterfeiting key points: It is necessary to verify the approval number H20153211 of the national drug standard on the drug packaging.

4 Precautions

(1) Adverse reactions: Common visual impairment, nausea and vomiting, etc. Regular monitoring of liver function is necessary.

(2) Taboo population: Patients with severe liver and kidney dysfunction need to adjust the dosage, and are prohibited during pregnancy.